SYMPATH
Reach α-synuclein-dependent neurodegeneration: clinical development of therapeutic AFFITOPE vaccines for Parkinson’s disease and multisystem atrophy
| Coordinatore | AFFIRIS AG
Organization address
address: KARL FARKAS GASSE 22 contact info |
| Nazionalità Coordinatore | Austria [AT] |
| Totale costo | 7˙699˙474 € |
| EC contributo | 5˙999˙706 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2013-INNOVATION-1 |
| Funding Scheme | CP-FP |
| Anno di inizio | 2013 |
| Periodo (anno-mese-giorno) | 2013-10-01 - 2017-09-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
AFFIRIS AG
Organization address
address: KARL FARKAS GASSE 22 contact info |
AT (WIEN) | coordinator | 2˙962˙400.00 |
| 2 |
FORSCHUNGSZENTRUM JUELICH GMBH
Organization address
address: Leo-Brandt-Strasse contact info |
DE (JUELICH) | participant | 789˙322.00 |
| 3 |
BIOLUTION GMBH
Organization address
address: Karl-Farkas-Gasse 22 contact info |
AT (WIEN) | participant | 685˙011.00 |
| 4 |
MEDIZINISCHE UNIVERSITAET INNSBRUCK
Organization address
address: Christoph-Probst Platz 1 contact info |
AT (INNSBRUCK) | participant | 366˙012.00 |
| 5 |
PROSENEX AMBULATORIUM BETRIEBSGMBH
Organization address
address: Schottenfeldgasse 45 contact info |
AT (Wien) | participant | 366˙012.00 |
| 6 |
CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE
Organization address
address: "Rue Viguerie, Hotel-Dieu Saint Jacques 2" contact info |
FR (TOULOUSE) | participant | 345˙936.00 |
| 7 |
CHU HOPITAUX DE BORDEAUX
Organization address
address: RUE DUBERNAT 12 contact info |
FR (TALENCE) | participant | 328˙764.00 |
| 8 |
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
Organization address
address: 101 Rue de Tolbiac contact info |
FR (PARIS) | participant | 156˙249.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'The goal of SYMPATH is to advance clinical development of therapeutic vaccines targeting α-synuclein (aSyn)-driven neurodegenerative diseases (ND). It addresses Parkinson’s disease (PD) and multiple system atrophy (MSA), two synucleopathies, for which no causal therapy exists. Ultimately, both lead to patient disability and death, which along with patient number (PD) and age of onset (MSA, PD) define their high medical need status. The proposed programme focuses on 2 vaccine candidates, PD01A and PD03A, delivered by the innovative AFFITOME® technology. Both are peptide-protein conjugate vaccines and first-in-class candidates. They were selected to elicit antibodies neutralizing aSyn but sparing compensatory β-synuclein. Pre-clinical evaluation confirmed their disease-modifying activity in various models. The unprecedented clinical approach, called TANDEM strategy, uses the synergy resulting from applying 2 vaccine candidates in 2 complementary indications linked through their pathology. TANDEM PD/MSA capitalizes on (i) excellent clinical research centres and their associated national/European networks, (ii) platform methods assessing aSyn species as candidate biomarkers and (iii) preliminary clinical experience with PD01A, the first aSyn targeting vaccine ever tested in humans. Its core is formed by 2 phase I studies testing PD01A in MSA and PD03A in PD/MSA. Importantly, trial design (duration, endpoints, vaccine dose and schedule) will ensure collection of initial biomarker data connecting clinical results of PD- and MSA trajectories. SYMPATH defines the logical next development step of both AFFITOPE® vaccine candidates for synucleopathies and generates information/material (biobank) rendering them more amenable to rational drug development. Successful completion of the programme promises reaching aSyn pathology with an active vaccine as a causal therapy for PD/MSA, thus advancing one or both candidates as prime targets for product development and investment.'
Introduzione (Teaser)
Parkinson's disease ranks amongst the most common neurodegenerative disorders. European researchers are working on the first therapeutic vaccines that could improve disease outcome.